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Introduction
In patients with diffuse large B- cell lymphoma (DLBCL), 
the most common subtype of malignant lymphoma world-
wide, bone marrow involvement (BMI) is known to be 
a poor prognostic factor for patient outcome. BMI is 
categorized as extranodal site involvement and Ann- Arbor 
stage IV disease and is therefore associated with the 
International Prognostic Index (IPI), the most reliable 
prognostic indicator of lymphoma patients [1–3]. Even 
in the rituximab era, BMI remains a poor prognostic 
factor for DLBCL patients [4, 5]. In published studies, 
approximately 10% of DLBCL cases exhibited bone mar-
row involvement at the time of diagnosis [2–5].
Bone marrow biopsies and aspirations sampled from 
the iliac crest bone, which are the conventional means 
of BMI detection, are notorious for their high false- negative 
rates [2, 3, 5]. To overcome this limitation, the usefulness 
of ancillary tests, including immunoglobulin gene rear-
rangement study, flow cytometry and immunohistochem-
istry, have been evaluated. Previous studies show that these 
ancillary tests can improve the detection rate of BMI and 
predict the outcome of DLBCL patients. Among them, 
detection of monoclonal immunoglobulin gene 
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Abstract
Bone marrow involvement (BMI) is a well- known poor prognostic factor in 
patients with diffuse large B- cell lymphoma (DLBCL). This study robustly in-
vestigated the significance of monoclonal immunoglobulin gene rearrangement 
combined with histologic B- cell aggregates in bone marrow (BM) in the detec-
tion of a poor prognostic group. Pretreatment BM samples of 394 DLBCL 
patients were analyzed via the immunoglobulin gene rearrangement study and 
the microscopic examination. Monoclonal immunoglobulin gene rearrangement 
was detected in 25.4% of cases. Histologic B- cell aggregates with the features 
of large B- cell lymphoma aggregates, small cell B- cell lymphoma aggregates, or 
B- cell aggregates of unknown biological potential were observed in 12% of cases 
(6.9%, 1.3%, and 3.8%, respectively). Histologic B- cell aggregates were more 
associated with monoclonality than polyclonality. Cases with both monoclonality 
and histologic B- cell aggregates demonstrated close association with poor prog-
nostic factors such as a higher International Prognostic Index score and showed 
an inferior overall survival rate when compared to cases with only monoclonality 
or only histologic B- cell aggregates. From the findings, a combination of mono-
clonality and histologic B- cell aggregates within the bone marrow was highly 
associated with poor prognosis and could be used to determine high- risk DLBLC 
patients with greater sensitivity and specificity than conventional microscopic 
examination or immunoglobulin gene rearrangement study alone.
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rearrangement has been considered as an alternative tool 
for detecting minimal tumor cells [6, 7]. However, the 
implications of detecting monoclonal immunoglobulin gene 
rearrangement in conjunction with histologic B- cell aggre-
gates have not been robustly studied in terms of patient 
prognosis. In this study, the clinical value of monoclonal 
immunoglobulin gene rearrangement in conjunction with 
histologic B- cell aggregates was investigated in a large 
number of DLBCL patients.
Methods
Patients and samples
Pretreatment bone marrow samples of patients with dif-
fuse large B- cell lymphoma (DLBCL) were analyzed for 
this study. Patients were diagnosed with DLBCL according 
to the World Health Organization classification criteria 
[1] at Severance Hospital from July 2010 to March 2015. 
Among the total number of patients diagnosed as DLBCL, 
394 cases were selected for this study according to the 
inclusion criteria: results of both the immunoglobulin gene 
rearrangement study and the histologic assessment were 
available based on the quality of the bone marrow speci-
men. Information on clinicopathologic factors, treatment, 
and survival data were obtained from the medical records. 
Systemic chemotherapy was performed in 92% of cases 
(363 of 394), and 74% of the patients (292 of 394) were 
treated with rituximab. The Institutional Review Board 
approved this study.
Histologic assessment of bone marrow 
involvement and immunoglobulin gene 
rearrangement study
The trephine bone marrow biopsy specimens were sampled 
for lymphoma staging before therapy. The histology of 
each trephine bone marrow biopsy was reviewed by 
hematopathologists. Sample adequacy was evaluated grossly 
and microscopically. The formalin- fixed paraffin- embedded 
(FFPE) tissue specimens of the bone marrow biopsy were 
stained with H&E, and immunohistochemical analysis of 
B- cell markers (CD20, CD79a, and/or PAX5) was per-
formed to detect B- cell proliferation. Bone marrow involve-
ment was defined according to histologic criteria and 
immunohistochemistry of B- cell markers [3, 4].
The histologic features of B- cell infiltration within bone 
marrow were defined as large B- cell lymphoma aggregates, 
small cell B- cell lymphoma aggregates, or B- cell aggregates 
of unknown biological potential. Proliferations of large 
and/or pleomorphic B cells with various patterns of para-
trabecular, interstitial, and/or diffuse growth were defined 
as large B- cell lymphoma aggregates [3, 4] (Fig. S1A and 
B). Proliferations of small- to medium- sized mature B 
cells that occupied large proportions of marrow surfaces 
and showed characteristic growth patterns indicative of 
malignant lymphoid aggregates such as paratrabecular 
location, infiltrative edges, inclusion of fat cells or loca-
tion surrounding large sinuses [8, 9] were defined as small 
cell B- cell lymphoma aggregates (Fig. S1C and D). Sparse 
collections of nonparatrabecular, interstitial aggregates of 
small- to medium- sized mature B cells were defined as 
B- cell aggregates of unknown biological potential because 
lymphoid aggregates of this category could not fulfill the 
criteria of lymphoma due to low cellularity and/or lack 
of histologic characteristics indicative of malignant lym-
phoid aggregates [8, 9] (Fig.S1E–H).
Bone marrow aspirates of the DLBCL patients were used 
for the detection of monoclonal gene rearrangement of 
immunoglobulin heavy (IgH) chain and immunoglobulin 
kappa (IgK) chain. PCR assays were performed using 
BIOMED- 2 multiplex primers according to the manufac-
turer’s protocol (InVivoScribe, San Diego, CA, USA). Reaction 
assays for IgH and IgK gene rearrangement tests included 
the full set of five reactions targeting IGH (IGHA: FR1- JH; 
IGHB: FR2- JH; IGHC: FR3- JH; IGHD: DH1–6- JH; IGHE: 
DH7- JH) and two reactions targeting IGK (IGKA: Vk- Jk; 
IGKB: Vk- Kde + intron- Kde) [10]. Cases showing monoclonal 
immunoglobulin gene rearrangement were defined as the 
mono clonality group, and cases showing polyclonal immu-
noglobulin gene rearrangement were defined as the poly-
clonality group. According to clonal status of immunoglobulin 
gene rearrangement and histologic B- cell aggregates, the cases 
were divided into the following four groups: both mono-
clonality and histologic B- cell aggregates, monoclonality only 
(monoclonality and absence of B- cell aggregates), histologic 
B- cell aggregates only (polyclonality and histologic B- cell 
aggregates) and no abnormality (polyclonality and absence 
of B- cell aggregates).
Statistical analysis
Differences between the variables examined were analyzed 
using Fisher’s exact test. Multiple logistic regression analysis 
was performed to examine the relationships of multiple 
parameters. Variables predictive of overall survival were 
analyzed using uni- and multivariate Cox proportional 
hazards models. Overall survival curves were estimated 
using the Kaplan–Meier method and compared using the 
log- rank test. Overall survival times were measured from 
the date of lymphoma diagnosis to the date of lymphoma- 
related death or the last follow- up visit. The average 
follow- up period was 24.7 months (range, 0.5–
66.0 months). A two- sided P value <0.05 was considered 
to be statistically significant. All statistical analyses were 
carried out using SPSS software, version 20.0 for Windows 
(IBM, Armonk, NY).
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Results
Patterns of immunoglobulin gene 
rearrangement and histologic features in 
bone marrow
The distribution of cases according to the clonal status 
of immunoglobulin gene rearrangement and histologic 
B- cell aggregates is presented in Figure 1. In the immu-
noglobulin gene rearrangement study, monoclonal IgH 
and/or IgK gene rearrangement was observed in 25.4% 
of cases (n = 100), and 74.6% of cases (n = 294) showed 
polyclonal immunoglobulin gene rearrangement. In the 
histologic analysis, large B- cell lymphoma aggregates were 
noted in 6.9% (n = 27), small cell B- cell lymphoma 
aggregates in 1.3% (n = 5), and B- cell aggregates of 
unknown biological potential in 3.8% (n = 15). Of the 
394 cases, 88.1% (n = 347) did not show B- cell aggregates. 
Among 100 cases showing monoclonal immunoglobulin 
gene rearrangement (the monoclonality group), histologic 
B- cell aggregates were noted in 37% of cases (37 of 100): 
25% with large B- cell lymphoma aggregates, 5% with small 
cell B- cell lymphoma aggregates, and 7% with B- cell 
aggregates of unknown biological potential. Within the 
monoclonality group, 63% of cases (63 of 100) did not 
show B- cell aggregates. Among the 294 cases showing 
polyclonal immunoglobulin gene rearrangement (the poly-
clonality group), 96.6% (n = 284) did not show B- cell 
aggregates. The remaining cases were two (0.7%) with 
large B- cell lymphoma aggregates and eight (2.7%) with 
B- cell aggregates of unknown biological potential. The 
proportion of histologic B- cell aggregates was higher in 
the monoclonality group than in the polyclonality group 
(37% vs. 3.4%; P < 0.001). Overall, 9.4% (n = 37) showed 
both monoclonality and histologic B- cell aggregates, 16% 
(n = 63) monoclonality only, 2.5% (n = 10) histologic 
B- cell aggregates only, and 72.1% (n = 284) no 
abnormality.
Monoclonal immunoglobulin gene 
rearrangement and histologic B- cell 
aggregates in association with 
clinicopathological factors
Overall associations of monoclonal immunoglobulin gene 
rearrangement and/or histologic B- cell aggregates with 
Figure 1. Venn diagram showing the relationships between clonal status of immunoglobulin gene rearrangement and histologic B- cell aggregates. 
Among 394 cases, 100 (green) showed monoclonal immunoglobulin gene rearrangement, 27 showed bone marrow involvement of large B- cell 
lymphoma aggregates (violet), five showed small cell B- cell lymphoma aggregates (scarlet), and seven showed B- cell aggregates of unknown biological 
potential (blue). The remaining 284 cases showed no abnormalities in both clonality and histologic B- cell aggregates
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clinicopathological variables were analyzed using Fisher’s 
exact test, summarized in Table 1. Monoclonality was 
more associated with the previously known poor prognostic 
factors of age >60 years, elevated lactate dehydrogenase 
(LDH), Eastern Cooperative Oncology Group (ECOG) 
performance score ≥2, extranodal site involvement ≥2, 
Ann- Arbor stage III/IV, and high IPI score than poly-
clonality. Histologic B- cell aggregates were also more 
associated with elevated LDH, extranodal site involvement 
≥2, Ann- Arbor stage III/IV, and high IPI score than the 
absence of B- cell aggregates. Germinal center B- cell–like 
(GCB) type or non- GCB type DLBCL showed no associa-
tion with clonal status of immunoglobulin gene rearrange-
ment or histologic B- cell aggregates.
The proportion of patients with age >60, elevated 
LDH, ECOG performance score ≥2, extranodal site 
involvement ≥2, Ann- Arbor stage III/IV, and high IPI 
score was higher in the groups showing monoclonality 
and/or B- cell aggregates, particularly in the group show-
ing both monoclonality and B- cell aggregates, when 
compared with the group with no abnormalities (Fig. 2 
A–F). On multiple logistic regression analysis, intermedi-
ate or high IPI score as well as the individual IPI risk 
factors except age >60 were significantly related to the 
group with both monoclonality and B- cell aggregates. 
The factors of extranodal site involvement ≥2 and Ann- 
Arbor stage III/IV as well as an intermediate or high 
IPI score were independently related to the group with 
both monoclonality and B- cell aggregates. For the group 
with monoclonality only, the factors of age >60 and 
high IPI score were independently related. The group 
with B- cell aggregates only did not demonstrate signifi-
cant relations to the IPI risk factors (Table 2).
Association with patient survival
Cases showing monoclonal immunoglobulin gene rear-
rangement were associated with an inferior overall survival 
(OS) rate compared to cases with polyclonality (P = 0.020; 
Fig. 3A). According to histology, cases with histologic 
B- cell aggregates were more associated with an inferior 
OS rate than cases showing absence of B- cell aggregates 
(P = 0.017; Fig. 3B). When compared with cases showing 
no abnormalities (polyclonality and absence of B- cell 
aggregates), cases showing both monoclonality and his-
tologic B- cell aggregates showed an inferior OS rate 
(P = 0.006; Fig. 3C). Cases showing monoclonality only 
and cases showing histologic B- cell aggregates only showed 
no difference in OS compared to cases with no abnor-
malities (P = 0.208 and 0.512, respectively; Fig. 3C). On 
multivariate analysis for overall survival, however, mono-
clonality and/or B- cell aggregates did not show statistical 
significance as an independent prognostic factor; only the 
IPI score was revealed to be an independent prognostic 
factor for overall survival (Table 3).
Discussion
This study investigated the prognostic implications of the 
molecular detection of monoclonal immunoglobulin gene 
rearrangement in conjunction with the histologic detection 
of B- cell aggregates in the pretreatment bone marrow of 
Table 1. Monoclonal immunoglobulin gene rearrangement and histologic B- cell aggregates in association with clinicopathological factors.
Factors Category
Immunoglobulin gene rearrangement Histologic B- cell aggregates
Polyclonal 
(n = 284)
Monoclonal 
(n = 100)
P value Absence of B- cell 
aggregates (n = 347)
B- cell aggregates 
(n = 47)
P value
Diffuse large B- cell 
lymphoma (DLBCL) type
GCB 31.7% 27.6% 0.567 29.5% 40.6% 0.225
NGC 68.3% 72.4% 70.5% 59.4%
Age ≤60 51.7% 35.0% 0.005 49.0% 36.2% 0.120
>60 48.3% 65.0% 51.0% 63.8%
LDH Not elevated 56.6% 38.9% 0.003 55.5% 27.3% 0.001
elevated 43.4% 61.1% 44.5% 72.7%
ECOG PS <2 86.2% 72.9% 0.005 83.9% 75.0% 0.141
≥2 13.8% 27.1% 16.1% 25.0%
Extranodal site <2 77.5% 53.1% <0.001 75.1% 43.2% <0.001
≥2 22.5% 46.9% 24.9% 56.8%
Ann- Arbor stage I/II 60.0% 34.4% <0.001 58.2% 18.2% <0.001
III/IV 40.0% 65.6% 41.8% 81.8%
IPI score Low (0, 1) 48.6% 27.4% <0.001 47.0% 14.0% <0.001
Intermediate (2, 3) 40.5% 45.3% 40.2% 53.5%
High (4, 5) 10.9% 27.4% 12.8% 32.6%
GCB, germinal center B- cell like; NGC, non- GCB; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group performance score; 
IPI, International Prognostic Index.
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patients with diffuse large B- cell lymphoma (DLBCL). This 
study aimed to determine the prognostic implications of 
B- cell aggregates accompanying monoclonality in order 
to improve the sensitivity and specificity of bone marrow 
tests for bone marrow involvement in DLBCL patients. 
Thus, the prognostic significance of histologic aggregates 
of monoclonal B cells (both monoclonality and B- cell 
aggregates) was compared with that of monoclonality only 
(monoclonal immunoglobulin gene rearrangement and 
absence of B- cell aggregates), B- cell aggregates only (poly-
clonality and B- cell aggregates), and no abnormalities 
(polyclonality and absence of B- cell aggregates).
In this study, monoclonality was detected in 25.4% of 
cases, and monoclonality itself was closely related to poor 
prognostic factors such as high IPI scores and associated 
with inferior overall survival. In a previous study on the 
bone marrow staging of 155 DLBCL patients, 22.6% of 
cases (35 of 155) showed monoclonal immunoglobulin 
gene (IgH and/or IgK) rearrangement in the bone marrow 
aspirates and/or peripheral blood, and this monoclonality 
was related to inferior overall survival [6]. The positivity 
rate of monoclonality and the close association of mono-
clonality with inferior OS were similar to the present 
findings. These findings indicate that immunoglobulin gene 
rearrangement studies of bone marrow can be used to 
detect a poor prognostic group among DLBCL patients 
with higher sensitivity than conventional microscopic exami-
nation; bone marrow involvement (BMI) of DLBCL, which 
was defined by conventional histologic criteria [3, 4], was 
noted in only 6.9% of tested cases in this study. 
Monoclonality only (monoclonal immunoglobulin gene 
rearrangement and absence of B- cell aggregates), however, 
did not show independent association with known prog-
nostic factors except for the factor of age >60. In addition, 
monoclonality only showed no relation to patient survival. 
These findings indicate that monoclonality without the 
formation of B- cell aggregates may be related monoclonal 
B- cell lymphocytosis, an asymptomatic indolent syndrome 
wherein lower numbers of monoclonal B cells are present 
in the peripheral blood, usually in late adulthood and 
particularly in those older than 60 years. This condition 
is known to rarely progress into malignant lymphoma 
(specifically, chronic lymphocytic leukemia), and most cases 
show benign clinical features [11–13]. Pseudoclonality or 
false- positive results might also be suggested for cases with 
monoclonality only; however, the BIOMED- 2 multiplex 
PCR method is known to detect clonal B cells with high 
sensitivity and specificity [14, 15].
Proliferation of large B cells with various growth pat-
terns is defined as BMI of DLBCL based on previously 
reported criteria [3, 4]. Although several recent studies 
show that small cell B- cell lymphoma involvement cannot 
Figure 2. When compared to the rates of known prognostic factors (A–F) in the group with no abnormalities, the rates of age > 60 (A), elevated 
lactate dehydrogenase (LDH) (B), ECOG performance score ≥2 (C), extranodal site involvement ≥2 (D), Ann- Arbor stage III/IV (E), and high IPI score (F) 
were higher in the three groups with monoclonality only (monoclonality and absence of B- cell aggregates), B- cell aggregates only (polyclonality and 
B- cell aggregates), and both monoclonality and B- cell aggregates, particularly, in the group with both monoclonality and B- cell aggregates.
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independently predict a poor clinical outcome [3, 4], it 
should be noted that the determination of B- cell size 
within the bone marrow is frequently difficult, likely due 
to low cellularity, overflow of admixed hematopoietic 
precursors, or artificial atrophy during tissue processes 
such as decalcification and dehydration. These factors seem 
to be related to the high false- negative rate for BMI. We 
considered the implications of formation of lymphoid 
aggregates, as the histologic/structural growth pattern could 
be more easily detected at the microscopic level. In 
Figure 3. Cases showing monoclonal immunoglobulin gene rearrangement (Monoclonal) were associated with inferior overall survival (OS) rates 
compared to cases with polyclonal immunoglobulin gene rearrangement (Polyclonal) (A). Cases with histologic B- cell aggregates were more highly 
associated with an inferior OS rate than cases showing absence of histologic B- cell aggregates (B). When compared to cases showing no abnormalities, 
cases showing both monoclonality and histologic B- cell aggregates showed an inferior OS rate (C). Cases showing monoclonality only or cases 
showing B- cell aggregates only showed no difference in OS rate when compared with cases with no abnormalities (C). Survival function curves and 
survival rates were determined using the Kaplan–Meier method, and differences in survival rates were compared using the log- rank test.
Table 2. Multiple logistic regression analysis.
Group (vs. no 
abnormality) Variables
Univariate regression analysis Multivariate regression analysis
P value OR 95% CI P value OR 95% CI
Monoclonality only Age (>60 vs. ≤60) 0.007 2.2 1.2–3.9 0.020 2.1 1.1–3.8
LDH(elevated vs. normal) 0.171 1.5 0.8–2.6 0.874 1.1 0.6–2.0
ECOGPS(≥2 vs. <2) 0.023 2.1 1.1–4.2 0.183 1.6 0.8–3.4
Extranodal site(≥2 vs. <2) 0.035 1.9 1.0–3.4 0.128 1.7 0.9–3.4
Ann- Arbor stage (III–IV vs. I–II) 0.085 1.6 0.9–2.8 0.888 0.5–2.1
IPI scores (vs. low risk)
Intermediate risk 0.551 1.2 0.7–2.2
High risk 0.012 2.7 1.2–5.8
B- cell aggregates only Age (>60 vs. ≤60) 0.177 2.6 0.7–10.2 0.208 2.5 0.6–10.1
LDH(elevated vs. normal) 0.29 2.0 0.6–7.3 0.37 1.9 0.5–7.6
ECOGPS(≥2 vs. <2) 0.725 0.7 0.1–5.6 0.449 0.4 0.1–3.7
Extranodal site(≥2 vs. <2) 0.85 0.9 0.2–4.1 0.727 0.7 0.1–4.1
Ann- Arbor stage (III–IV vs. I–II) 0.514 1.5 0.4–5.4 0.711 1.3 0.3–5.6
IPI scores (vs. low risk)
Intermediate risk 0.347 2.3 0.4–13.2
High risk 0.793 1.2 0.3- 4.9
Both monoclonality 
and B- cell 
aggregates
Age (>60 vs. ≤60) 0.098 1.8 0.9–3.7 0.555 1.3 0.6–2.8
LDH(elevated vs. normal) 0.001 4.3 1.9–9.9 0.205 1.8 0.7–4.5
ECOGPS(≥2 vs. <2) 0.022 2.6 1.1–5.8 0.62 1.3 0.5–3.1
Extranodal site(≥2 vs. <2) <0.001 7.2 3.3–15.5 0.007 3.2 1.4–7.4
Ann- Arbor stage (III–IV vs. I–II) <0.001 15.7 4.7–52.7 0.003 7.1 1.9–26.2
IPI scores (vs. low risk)
Intermediate risk 0.001 11.5 2.6–50.3
High risk <0.001 27.7 5.9–130.6
The analysis for IPI scores was independently performed as the factors (age, lactate dehydrogenase (LDH), ECOGPS, extranodal site involvement, Ann- 
Arbor stage) included IPI risk stratification by definition. OR, odds ratio; 95%CI, 95% confidence interval for odds ratio.
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addition, the possible limitations of microscopic examina-
tion might have been reduced, as structural changes may 
have been relatively less affected by artifacts such as tissue 
processes. Although small (<600 μm) nonparatrabecular, 
well- circumscribed aggregates of small- to medium- sized 
mature B cells within bone marrow have been considered 
to be benign lymphoid aggregates in previous studies [8, 
9], the clonal status of such B- cell aggregates was not 
robustly investigated in those studies. In fact, this study 
noted that the growth pattern of histologic B- cell aggre-
gates itself was closely related to poor prognostic factors 
such as high IPI scores and significantly associated with 
an inferior OS rate. These findings suggest that the growth 
pattern of histologic B- cell aggregates may have prognostic 
relevance. In addition, histologic B- cell aggregates can 
more sensitively detect a poor prognostic group of DLBCL 
patients; in this study BMI by conventional definition 
was noted in only 6.9% of cases, whereas histologic B- cell 
aggregates were noted in 12% of cases. B- cell aggregates 
only (polyclonality and histologic B- cell aggregates), how-
ever, did not show independent association with the known 
poor prognostic factors or patient survival. In this study, 
most (80%, 2 of 10; Fig.1) cases showing B- cell aggregates 
only had histologic types of unknown biological potential. 
These present findings imply that polyclonal B- cell aggre-
gates, particularly histologic types of unknown biological 
potential, could be considered as benign lymphoid aggre-
gates. In other words, B- cell aggregates of unknown bio-
logical potential could be determined to be of benign or 
malignant biologic potential through the immunoglobulin 
gene rearrangement study.
To overcome the possible limitation of immunoglobulin 
gene rearrangement study or conventional microscopic 
histologic examination as a single test modality for BMI, 
we focused on the combination of monoclonality and 
histologic B- cell aggregates (i.e., monoclonal B- cell aggre-
gates). In terms of prognosis, patients with monoclonality 
in conjunction with histologic B- cell aggregates were 
determined to be the highest risk group. Poor prognostic 
factors such as high IPI scores were significantly related 
to cases with monoclonal B- cell aggregates (both mono-
clonality and B- cell aggregates). In addition, cases with 
both monoclonality and B- cell aggregates showed an infe-
rior OS rate compared to cases with no abnormalities. 
Cases with monoclonality only or B- cell aggregates only 
may be in the same risk group as cases showing no 
abnormalities in terms of DLBCL prognosis.
This study had several limitations. Although the mono-
clonal B- cell aggregates (both monoclonality and B- cell 
aggregates) revealed poor patient survival on univariate 
analysis, the factor was not determined to be an inde-
pendent prognostic factor on multivariate analysis. In 
particular, the observation time was relatively short. A 
longer time observation is necessary to assess the long- 
term effects of monoclonal B- cell aggregates in terms of 
patient prognosis.
In conclusion, histologic B- cell aggregates were found 
to be significantly associated with monoclonality. 
Monoclonality combined with histologic B- cell aggregates 
within the bone marrow was most highly associated with 
poor prognosis and could be used to detect high- risk 
DLBLC patients with greater sensitivity and specificity 
than conventional microscopic examination only or immu-
noglobulin gene rearrangement study only.
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Table 3. Univariate and multivariate Cox proportional hazards models for overall survival.
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Extranodal site(≥2 vs. <2) 0.352 1.2 0.8–1.9
Ann- Arbor stage (III–IV vs. I–II) <0.001 2.3 1.5–3.5
IPI scores (vs. low risk)
Intermediate risk <0.001 3.3 1.9–5.6 <0.001 3.2 1.8–5.5
High risk <0.001 4.9 2.6–9.1 <0.001 4.6 2.4–8.6
The case group (vs. no abnormality)
Monoclonality only 0.209 1.4 0.8–2.4 0.442 1.2 0.7–2.1
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. (A) A representative case of the involvement 
of large B- cell lymphoma (DLBCL) that shows diffuse 
proliferation of large B cells (A and B). A representa-
tive case of involvement of small cell B- cell lymphoma 
that shows small- to medium- sized low- grade mature 
B cells in patterns of large aggregates of infiltrative 
edges, occupying large proportions of marrow surfaces 
(C and D). Representative cases of small nonparatra-
becular, interstitial aggregates of small- to medium- sized 
mature B cells, which did not fulfill the criteria of 
lymphoma due to low cellularity of the proliferating B 
cells or lack of histologic characteristics for malignant 
lymphoid aggregates (E–F and G–H). Figures of H&E 
staining and CD20 immunostaining were captured at 
×200 magnification. Figures of insets show more details 
of tumor cells.
